1. Recurrent intrapulmonary malignant small cell tumor of the thoracopulmonary region with metastasis to the oral cavity: review of literature and case report.
- Author
-
Hicks MJ, Smith JD Jr, Carter AB, Flaitz CM, Barrish JP, and Hawkins EP
- Subjects
- Adolescent, Humans, Immunohistochemistry, Lung Neoplasms chemistry, Lung Neoplasms genetics, Male, Mouth Neoplasms chemistry, Mouth Neoplasms pathology, Sarcoma, Small Cell chemistry, Sarcoma, Small Cell genetics, Sarcoma, Small Cell secondary, Translocation, Genetic, Lung Neoplasms pathology, Mouth Neoplasms secondary, Neoplasm Recurrence, Local, Sarcoma, Small Cell pathology
- Abstract
Malignant small cell tumor of the thoracopulmonary region (MSCT) was first described in 1979 and has been referred to as the Askin tumor. This malignant neoplasm is a member of the peripheral primitive neuroectodermal tumor (PPNET) family and typically involves the periosteum, soft tissue, and extrapulmonary tissue of the thoracic wall. MSCT may also involve the lung parenchyma by local extension or may arise de novo in peripheral lung tissue. Local recurrence, abdominal involvement by tumor extravasation across the diaphragm, and skeletal metastatic disease are relatively common. However, metastasis to the head and neck region and in particular to the oral cavity is extremely rare. We present a recurrent intrapulmonary MSCT with metastasis to the oral cavity in an adolescent Hispanic boy, and review the literature regarding this member of the PPNET family. Differentiation from neuroblastoma may be made based on immunoreactivity for beta 2 microglobulin and HBA71 and lack of immunoreactivity for chromogranin in PPNET and MSCT. Ultrastructural features commonly seen in MSCT and PPNET are round to ovoid tumor cells with occasional cytoplasmic processes with relatively few pleomorphic dense core granules. These tumors lack the gangliocytic and Schwann cell differentiation that is characteristic of neuroblastoma. MSCT and PPNET have a common reciprocal cytogenetic translocation [t(11;22)q(24;q12)], which is shared with Ewing's sarcoma. Prognosis in MSCT is quite dismal, with a 2-year survival of 38% and a 6-year survival of only 14%.
- Published
- 1995
- Full Text
- View/download PDF